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Abstract: Cardiosphere-derived cells (CDCs) are progenitor cells derived from heart tissue and have
shown promising results in preclinical models. APOSEC, the secretome of irradiated peripheral blood
mononuclear cells, has decreased infarct size in acute and chronic experimental myocardial infarction (MI).
We enhanced the effect of CDCs with APOSEC preconditioning (apoCDC) and investigated the reparative
effect in a translational pig model of reperfused MI. Supernatants of CDCs, assessed by proteomic analysis,
revealed reduced production of extracellular matrix proteins after in vitro APOSEC preconditioning. In
a porcine model of catheter-based reperfused anterior acute MI (AMI), CDCs with (apoCDC, n = 8)
or without APOSEC preconditioning (CDC, n = 6) were infused intracoronary, 15 min after the start
of reperfusion. Untreated AMI animals (n = 7) and sham procedures (n = 5) functioned as controls.
2-deoxy-2-(18 F)-fluoro-D-glucose-positron emission tomography-magnetic resonance imaging ([18F]FDG-
PET-MRI), with late enhancement after 1 month, showed reduced scar volume and lower transmurality
of the infarcted area in CDC and apoCDC compared to AMI controls. Segmental quantitative PET
images displayed indicated more residual viability in apoCDC. The left-ventricle (LV) ejection fraction
was improved nonsignificantly to 45.8% ± 8.6% for apoCDC and 43.5% ± 7.1% for CDCs compared
to 38.5% ± 4.4% for untreated AMI. Quantitative hybrid [18F]FDG-PET-MRI demonstrated improved
metabolic and functional recovery after CDC administration, whereas apoCDCs induced preservation of
viability of the infarcted area.
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Cardiosphere-derived cells (CDCs) are progenitor cells derived
from heart tissue and have shown promising results in preclin-
ical models. APOSEC, the secretome of irradiated peripheral
blood mononuclear cells, has decreased infarct size in acute
and chronic experimental myocardial infarction (MI). We
enhanced the effect of CDCs with APOSEC preconditioning
(apoCDC) and investigated the reparative effect in a transla-
tional pig model of reperfused MI. Supernatants of CDCs, as-
sessed by proteomic analysis, revealed reduced production of
extracellular matrix proteins after in vitro APOSEC precondi-
tioning. In a porcine model of catheter-based reperfused ante-
rior acute MI (AMI), CDCs with (apoCDC, n = 8) or without
APOSEC preconditioning (CDC, n = 6) were infused intracoro-
nary, 15 min after the start of reperfusion. Untreated AMI an-
imals (n = 7) and sham procedures (n = 5) functioned as con-
trols. 2-deoxy-2-(18 F)-fluoro-D-glucose-positron emission
tomography-magnetic resonance imaging ([18F]FDG-PET-
MRI), with late enhancement after 1 month, showed reduced
scar volume and lower transmurality of the infarcted area in
CDC and apoCDC compared to AMI controls. Segmental
quantitative PET images displayed indicated more residual
viability in apoCDC. The left-ventricle (LV) ejection fraction
was improved nonsignificantly to 45.8% ± 8.6% for apoCDC
and 43.5% ± 7.1% for CDCs compared to 38.5% ± 4.4% for un-
treated AMI. Quantitative hybrid [18F]FDG-PET-MRI demon-
strated improved metabolic and functional recovery after CDC
administration, whereas apoCDCs induced preservation of
viability of the infarcted area.
INTRODUCTION
After almost 20 years of intense research and recent setbacks in clin-
ical evaluations, the utility, risks, and efficacy of intracoronary cell
administration are controversially debated.1,2 The main, generally
accepted mechanism of eventual improvement in cardiac function
in experimental and some clinical studies is a paracrine effect caused
by secreted factors.3 A recent report identified a contribution of an
acute immune response through induction of macrophages to the
functional recovery after myocardial infarction (MI).4 Cardiac pro-
genitor cells appear to have superior effects compared to mesen-
chymal stem cells, the latter of which are easily available and
frequently used in clinical trials5 but have overall yielded insufficient
clinical benefit.
Cardiosphere-derived cells (CDCs) are a mixture of mesenchymal,
stromal, and progenitor cells derived from cultures of myocardial bi-
opsies.6 Preclinical and clinical studies demonstrated that intracoro-
nary delivery of allogeneic CDCs, directly after reperfusion of acute
MI (AMI), is effective in cardioprotection, prevents microvascular
obstruction, and attenuates adverse acute remodeling.7,8
It has been demonstrated that CDCs induce cardiac reparative mech-
anisms, despite only minimal direct cardiomyogenic differentiation,
which fails to contribute meaningfully to their beneficial effects.9
Their therapeutic activity is mainly due to distinctive impacts onmac-
rophages and paracrine effects, mediated by a mixture of cytokines,
including angiogenic and homing factors,5 but also by exosomal con-
tents, such as microRNAs (miRNAs).10 The cardiac repair capacity of
CDCs was assessed in randomized clinical trials in humans (Cardio-
sphere-Derived Autologous Stem Cells to Reverse Ventricular
Dysfunction [CADUCEUS] and Intracoronary Allogeneic Heart
Stem Cells to Achieve Myocardial Regeneration [ALLSTAR]) in the
subacute phase of AMI in a limited number of patients with initially
promising results in terms of a decrease in infarct size, which, howev-
er, did not result in a significant increase in global left-ventricle (LV)
ejection fraction (EF).11 Although the efficacy of CDCs after
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infarction appears not to be sufficiently robust for clinical application,
the modulation and enhancement of secreted factors of CDCs are still
attractive strategies for improving cell-based therapeutic implications.
Previous studies have demonstrated that administration of the secre-
tome of apoptotic peripheral blood cells (cell-free reparative therapy;
APOSEC; containing soluble factors derived from g-irradiated pe-
ripheral blood mononuclear cells [PBMCs]) results in cytoprotection
in the acute and chronic phase of AMI.12,13 In a large animal AMI
model, APOSEC prevented ventricular remodeling, abrogated
platelet aggregation, and promoted vasodilatation.14 The effect of
APOSEC was shown to be caused by a combination of different fac-
tors, including proteins, vesicle-derived short noncoding RNAs, and
lipids. Separate fractions, as well as secretomes of PBMC subpopula-
tions, failed to replicate completely the effects regarding tissue repair,
wound healing, and angiogenesis.15–17
Accordingly, we hypothesized that (1) preconditioning of CDCs with
APOSEC (apoCDC) enhances the survival and reparative function of
CDCs by influencing the paracrine effects through relevant cardiore-
generative factors and cytokines and (2) cardiac magnetic resonance
imaging (MRI), for assessing the beneficial effect in cardiac regener-
ation studies, is insufficiently sensitive for displaying increased
myocardial cell viability and perfusion. Therefore, we injected
apoCDCs to investigate a cardioprotective effect of intracoronary de-
livery of allogeneic apoCDCs directly after reperfusion of AMI and
compared the LV function and myocardial viability by quantitative
hybrid 2-deoxy-2-(18 F)-fluoro-D-glucose-positron emission tomog-
raphy-MRI ([18F]FDG)-PET-MRI) images with the animals receiving
nonconditioned CDCs, nontreated AMI, and sham-procedure
controls.
RESULTS
Coculture of APOSEC with CDCs Prevents Secretion of
Extracellular Matrix (ECM) Proteins and Increases Expression
and Secretion of Angiogenic and Homing Factors
We investigated apoCDCs for maximizing the prosurvival and secre-
tion-enhancing effects (Figure 1). Therefore, in a first step, we as-
sessed the effect of APOSEC on CDC in vitro and examined the con-
tent of secretory proteins with or without APOSEC supplementation
with a proteomic analysis. In order to facilitate the proteome analysis,
cells were incubated in the absence of serum.
To distinguish between components of APOSEC and proteins
secreted into the supernatant by CDCs, we analyzed quantitative pro-
tein differences between baseline and end of the incubation period.
The proteomics data identified protein clusters that were secreted
significantly stronger into the extracellular space by CDCs when
cultured without APOSEC on the one hand and original components
of APOSEC on the other hand. A continuous increase of proteins allo-
cated to a distinct cluster during the 72-h incubation time indicates
secretion by CDCs, whereas a sharp increase after addition of APO-
SEC signifies that the respective proteins are inherent constituents of
the PBMC secretome (Figure 2; Tables 1 and S1). Regarding the
reduced secretion of proteins upon incubation with APOSEC, Gene
Ontology (GO) analysis showed a strong association of these proteins
with ECM and cell adhesion and binding (Figure 2; Tables S2 and S3).
The GO terms are overlapping, indicating a shift of the paracrine
phenotype of CDCs under standard culture conditions toward secre-
tion of ECM remodeling proteins. Several collagens, including the
major myocardial collagens I and III, other ECM proteins (lamins,
laminins, fibronectin, lysyl oxidase 2), and proteins that are essential
for cell adhesion and protein binding, such as actinin, fibrinogen, and
periostin, were secreted significantly stronger in the native cell culture
(i.e., in the absence of APOSEC).
A limited number of proteins—a few guanosine triphosphate (GTP)-
binding proteins—were found to be secreted stronger by CDCs upon
incubation with APOSEC (Table 1). This apparently indicates a tran-
sition of CDCs under serum-free cell-culture conditions toward amy-
ofibroblast-like phenotype and a protecting effect of APOSEC on
CDCs. An influence of serum deprivation during the incubation
time might be possible. However, no detrimental effects on cell
viability and morphology were detected (Figure S1).
As previously documented for human APOSEC,16 a considerable
number of proteins were detected in porcine APOSEC-conditioned
medium before the start of CDC preconditioning. The concentrations
of the majority of these proteins remained constant during the 72-h
incubation period; i.e., they were not further secreted by CDCs. APO-
SEC is produced from apoptotic PBMCs, and the expected enrich-
ment of proteins found in neutrophils and other blood cells and pro-
teins induced by cellular stress was confirmed (Figures S2 and S3).
Together with lipids, miRNAs, extracellular vesicles (EVs), and
potentially other components, these proteins contribute to the repar-
ative capacity of APOSEC.
The electrospray ionization-mass spectrometry (ESI-MS) analysis in-
cludes proteins above the detection limit of the method. Therefore, we
specifically analyzed expression and secretion of low-abundant pro-
teins for angiogenesis (vascular endothelial growth factor [VEGF])
and stem-cell signaling (transforming growth factor b1 [TGFb1])
and homing (C-X-C motif chemokine ligand 12 [CXCL12]). VEGF
secretion into the cell-culture supernatant was increased by APOSEC
conditioning in a time- and concentration-dependent manner (Fig-
ure 2). Gene expression of CXCL12 was increased around 2-fold
over CDCs cultured in standard cell-culture medium (72 h).
CXCL12 protein levels in the cell-culture supernatant showed a
nonsignificant increase, indicating that upregulation of CXCL12 pro-
duction is slower than VEGF regulation. Taken together, these results
confirmed a prosurvival and proangiogenic effect of APOSEC on
CDCs and served as the basis for selecting the dose and pretreatment
duration for in vivo evaluations.
Effects of CDCs with and without APOSEC Preconditioning in a
Large Animal AMI Model
We used a translational large animal model to assess effects of
apoCDCs for treating AMI-induced heart failure, analyzed by
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 18 September 2020 355
cardiac [18F]FDG-PET-MRI with late enhancement (LE) after
3 days and 1 month. Comparative representative PET polar map im-
ages with simultaneous MRI infarct transmurality maps of the 3
AMI groups, as well as separate MRI and PET images, are displayed
in Figure 3. AMI scar size was significantly reduced after 1 month by
both CDCs (13.2% ± 2.8%) and apoCDCs (13.1% ± 7.4%) as
compared to untreated AMI animals (21.4% ± 2.3%) (Figure 3C).
LV EF was improved compared to untreated AMI but failed to reach
statistical significance (p = 0.13; CDC: 43.5% ± 7.1%, apoCDC:
45.8 ± 8.6, and untreated AMI: 39.8% ± 6.1%). 3-day LV end-dia-
stolic volume (EDV) and end-systolic volume (ESV) were similar
in all groups (Figure S6), but they were lower at the 1-month
follow-up in both CDC and apoCDC groups, as compared to un-
treated AMI group. After normalization to body weight, LV EDV
and ESV were both significantly reduced in apoCDC compared to
controls and CDC (Figure 3C). Infarct size decreased significantly
both in apoCDC (6.7% ± 6.8%) and CDC (8.4% ± 6.7%) as
compared to the untreated AMI group (1.1% ± 6.7%) between
3 days and 1 month. LV EF increased in apoCDC (5.9% ± 6.3%)
and CDC (4.0% ± 2.2%) but not the untreated AMI groups
(1.3% ± 7.7%); differences between the groups were not statisti-
cally significant.
The average transmurality of the scar region was reduced when
comparing the entire heart and the AMI segments. Segmental trans-
murality was significantly lower in mid anteroseptal, inferoseptal, and
apical segments, both in CDC and apoCDC groups compared to un-
treated AMI groups (Figure 4A).
Standardized [18F]FDG tracer uptake was significantly higher in the
apico-septal and apico-anterior and apex regions in the apoCDC an-
imals as compared to untreated AMI pigs, whereas the CDC group
showed a significantly higher uptake in the apico-anterior region
(Figure 4B).
Figure 1. Study Design
(A) Porcine PBMCs were isolated and irradiated. Apoptotic PBMCs were further incubated in vitro for 24 h, and the supernatant of the apoptotic PBMCs (APOSEC) was
collected. (B) Porcine CDCs were incubated with (apoCDC) or without APOSEC, and the cells were stored in liquid nitrogen. The secretome of CDCs and apoCDCs was
analyzed by proteomics. (C) Pigs underwent 90 min occlusion of the mid-LAD and were randomized to receive CDCs (107 cells) with or without APOSEC in vitro pre-
conditioning by intracoronary infusion during the reperfusion phase. [18F]FDG-PET-MRI imaging was performed 3 and 30 days later, and follow-up examinations were done
at indicated time points.
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Figure 2. Quantitative Changes of Secreted Proteins and Effect on Gene Expression In Vitro in Serum-Free or APOSEC-Containing Medium
CDCs were incubated with medium, with or without APOSEC, and supernatants were collected at 48 and 72 h and compared to baseline. Data are from three technical
replicates for each of three independent experiments. (A) Relative individual protein quantities were assessed by ESI-MS proteomics analysis, normalized, and summarized
(legend continued on next page)
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 18 September 2020 357
APOSEC preconditioning led to a significantly lower number of
transmural and nontransmural MRI-derived segments, whereas
CDC treatment resulted in a significantly lower number of trans-
mural segments in MRI, compared to the untreated AMI group
(Figure 5). The composite number of nonviable segments and seg-
ments with reduced viability was significantly lower in both
apoCDC (6.1 ± 1.6, p < 0.001) and CDC (6.3 ± 3.1, p = 0.01)
compared to untreated AMI animals (13.0 ± 4.3). This highlights
the higher sensitivity of [18F]FDG-PET imaging in assessment of
cardiac repair.
After pooling segmental PET uptake and MRI transmurality data of
all segments of all animals, [18F]FDG tracer uptake showed a signif-
icant negative correlation with infarct transmurality only at 1month,
indicating a mismatch between segmental transmurality and
viability data early (3 days) after reperfused AMI, probably due to
myocardial stunning or enhanced infiltration of inflammatory cells
(Figure S4).
The 30-day right-ventricle (RV) MRI results are shown in Figure S5,
with significant (p < 0.05) difference between sham control and all
AMI groups regarding RV EF, which might be explained by the
smaller scar size of the mid- and apical-interventricular septum.
The 3-day scar and LV and RV data are shown in Figures S6 and
S7, displaying no statistical difference among the 3 AMI groups at
this time point.
Effect of Regenerative Treatment on Gene and miRNA
Expression in AMI, Border, and Remote Myocardium
We separately analyzed gene expressions in the myocardium directly
affected by infarction (AMI), the adjacent area (border), and unaf-
fected (remote) tissue to examine molecular mechanisms of regener-
ation in distinct areas. Hearts were explanted 1 month after infarction
and treatment and used for analyzing tissue expression of selected
genes and miRNAs to detect long-term effects of the distinct treat-
ments. In our experiment, connexin 43 (CX43, gap junction protein
1 [GJA1]) expression was significantly lower after AMI compared
to healthy animals, and both CDC groups showed a restoration of
CX43 expression in the AMI zone (Figure 6).
The CXCL12 (SDF-1)/CXCR4 axis is instrumental for stem and pro-
genitor recruitment after MI. Our results show a marked increase of
CXCL12 expression in response to AMI in the infarct, border, and
remote zones. Particularly in the infarct zone, expression was further
enhanced in the apoCDC and CDC groups.
The cardiac-specific microRNA-1 (miR-1) has been shown to be
downregulated in areas of acute infarction and upregulated in non-
infarcted areas in human autopsy samples.18,19 The regulation of
miR-1 is known to be triggered shortly after the onset of infarction.
We found a similar pattern in nontreated infarcted pig hearts
1 month after MI compared to the myocardium of control animals
and a nonsignificant trend toward increased miR-1 levels in
infarcted myocardium after treatment with CDCs or apoCDCs.
The expressional levels of miR-1 and its known molecular target
CX43
20 are inversely correlated.
In treated and untreated pig hearts, miR-126 expression was reduced
1 month after AMI in the infarcted areas but largely unchanged in the
border and remote zones. Regenerative treatments did not result in
significant expressional changes in comparison to untreated animals.
miR-146a showed minor changes in expression in treated animals
compared to both untreated infarcted pigs and sham-operated con-
trol pigs.
Table 1. Overview of In Vitro Secretion of Protein Clusters by CDCs in the Presence or Absence of APOSEC
GO Term Regulated Selected Regulated Proteins Myocardial Role
without APOSEC with APOSEC
ECM structural constituent [[ / (low) collagen 1,3, fibronectin, fibrinogen cardiac remodeling
Collagen binding [ / (low) decorin, nidogen, cathepsin B cardiac remodeling
Cell adhesion molecule binding [ / (high) calreticulin, HSP70, profilin cell-cell and cell-ECM interactions
Integrin binding [ / (medium) TIMP2, laminin alpha ECM adhesion
Actin binding / (low) / (high) actinin, actin-related proteins, gelsolin, profilin cytoskeleton components
Peptidase activity [ / (high) serpins, complement C3 hemostase, fibrinolysis
Glycosaminoglycan binding [ [ biglycan, apoE, periostin ECM interactions, lipoproteins
Neutrophil-mediated immunity / (low) / (high) aldolase, calpain, hemoglobin immune response
Platelet degranulation / (low) / (high) pro-platelet basic protein, alpha globulin inflammatory processes
Time-dependent changes are presented in Figure 2. GO, gene ontology; ECM, extracellular matrix; HSP70, heat shock protein 70; TIMP2, tissue inhibitor of metalloproteinase 2.
for the indicated GO terms. Error bars are SEM. Arrows show addition of APOSEC, delineating the components of APOSEC from secreted proteins. Individual protein values
with statistical evaluations are shown in Table S1. (B) GO enrichment analysis of proteins detected in the proteome analysis with significantly increased secretion by CDCs in
standard medium, as opposed to APOSEC conditioning. (C) Concentration of VEGF and CXCL12 in cell-culture supernatants, measured by ELISA, and gene expression of
CDCs after 72 h incubation, with or without APOSEC. Data are mean ± SD.
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DISCUSSION
In this work, we show for the first time the following: that (1) precon-
ditioning of cardiac allogeneic CDCs with APOSEC preserves the
stem-cell properties and limits the production of proteins involved
in cross-differentiation toward a myofibroblast-like phenotype; (2)
cardiac MRI + LE might be insensitive to show detailed regenerative
effects of cardiac-regenerative stem cells; (3) [18F]FDG-PET imaging
is more attractive to demonstrate preserved viability of the ischemic-
injuredmyocytes, being subjected to paracrine-reparative influence of
stem cells; (4) simultaneous acquisition of [18F]FDG and MRI images
analyzed with custom-made software provides supplementary infor-
mation on segmental viability and transmurality; and (5) precondi-
tioned CDCs with paracrine stimuli lead to smaller areas with trans-
mural and nonviable myocardium and an improvement in LV EDV
(LVEDV) and ESV relative to body weight in a preclinical model of
reperfused AMI.
apoCDC
APOSEC has anti-inflammatory and cell-protective effects and has
been extensively characterized in vitro and in vivo.13,17,21,22 Clinical
development for a topical application for wound healing in diabetic
foot ulcers has been initiated. Direct induction of cardiac repair by
APOSEC after AMI in pigs was evaluated earlier.13,14 Here, we have
investigated the effect of in vitro conditioning of CDCs with the
cell-protective, prosurvival, and proangiogenic APOSEC. In vitro
culturing of CDCs in the presence of APOSEC significantly altered
the molecular properties of CDCs in terms of proteome secretion
and selected markers of gene expression. Overall, CDCs under stan-
dard, serum-free cell-culture conditions increasingly secreted ECM
proteins, indicating a certain degree of cross-differentiation toward
a myofibroblast-like phenotype. In contrast, APOSEC preserves the
characteristics of CDCs in vitro for at least 72 h. The use of APOSEC
(or similar medium additives) may be useful for in vitro propagation
of cardiac progenitor cells and for modulating and enhancing thera-
peutic effects.
Simultaneous Assessment of Cardiac Function and Myocardial
Viability
Both CDCs and apoCDCs resulted in smaller scar sizes, as deter-
mined by cardiac MRI, 1 month after the onset of infarction. We
have previously shown that intravenous application of APOSEC in
small and large animal AMI significantly reduced scar size and
improved LV EF.12 In previous experiments, intracoronary adminis-
tration of APOSEC in the reperfusion phase of AMI failed to improve
effects of intravenous APOSEC infusion (unpublished data). There-
fore, we did not compare the in vivo effects of intracoronary CDCs
and APOSEC in this study but investigated the APOSEC-enhanced
CDC effects on myocardial performance. The reduction of the LV
EF after 1 month was mitigated by cell treatment, but differences be-
tween CDC/apoCDC and untreated animals failed to reach signifi-
cance. This finding is in line with previous investigations in large an-
imal models and in clinical trials, showing that stem-cell
transplantation fails to result in a clinically meaningful improvement
of heart function in most cases.23 In order to gain further insight into
cell-therapy mechanism, we used hybrid cardiac MRI + LE with [18F]
FDG-PET imaging by a clinical camera. Increased uptake of the PET
tracer in apical anterior and septal segments indicates beneficial ef-
fects of cell treatment and in a higher extent after CDCs were precon-
ditioned with APOSEC. We analyzed both images by using the 17-
segment model and revealed small but significant changes in
ischemic-injured cell viability and transmurality in the cell-treated
groups. This is the first report on simultaneous quantitative assess-
ment of hybrid PET-MRI images.24 The discrepancy between viability
assessment by [18F]FDG-PET and MRI might reflect a higher sensi-
tivity of PET tracer imaging. Additionally, in the acute and subacute
phase of AMI, the increased [18F]FDG uptake might be caused by a
detection of infiltrating cells of the immune system or progenitor
cells, which enhances glucose uptake.25 However, infiltration of acti-
vated immune cells is regarded to be negligible 1 month after MI.
Several advantages and drawbacks, as well as challenges associated
with PET and MRI, respectively (Table 2), are well known.26 For
assessment of therapeutic values of cardiac repair modalities, [18F]
FDG-PET and hybrid PET-MRI systems may be superior for precise
assessment of beneficial effects.
Overall, these results are in line with the current knowledge of cardiac
regeneration by progenitor cells in large animal models and the clin-
ical setting. In our model, apoCDC failed to demonstrate a significant
increase in LV EF, but it improved LVEDV and LV ESV (LVESV)
relative to body weight and increased the viability of the myocardial
cells and decreased infarct size and the number of segments with
reduced or nonviable cardiomyocytes, keeping the door open for
further recovery. The effects on heart function observed in our study
may be improved by further optimizing preconditioning of CDCs
through improving APOSEC concentration or composition. Previous
Figure 3. Representative [18F]FDG-PET-MRI PolarMap Imagingwith Late Enhancement of Porcine Hearts after AMI and Treatment with apoCDCs, CDCs, or
Saline (AMI Untreated) at 3 Days and 1 Month and Summary of Functional Parameters Detected by PET-MRI Imaging
(A) At 3 days, similar-sized transmurality (red color) was detected in all 3 groups, with decreasing transmurality in CDC and apoCDC groups at the 1-month follow-up period
(FUP). Reduced viability was found in the anteroseptal region with visual smaller size of nonviable and reduced viable areas both at 3 days and 1 month FUP in the apoCDC
group. (B) MRI and MRI-PET fusion images. Group CDC (left): MRI showed myocardial thinning and increased signal intensity in the mid-anteroseptal/apical anterior
segments. MRI-PET fusion image indicated reduced tracer uptake in the same region (arrows). Group apoCDC (middle): MRI showed high late-enhancement signal intensity
in the apical septal segment, and MRI-PET fusion image demonstrated tracer uptake in the same region (arrows). Group AMI untreated (right): a large infarct resulted in
myocardial thinning and delayed enhancement in the mid-anteroseptal and apical segments (arrows). MRI and PET image fusion was done for visualization purposes in 3D
Slicer software. (C) Scar area, LV EF, end-diastolic (LV EDV index [LVEDVi]), stroke volume (LV SV index [LVSVi]), and end-systolic (LV ESV index [LVESVi]) indices relative to
body weight and cardiac output were assessed by cardiac MRI, 1 month after infarction and cell treatment. *p < 0.05, ***p < 0.001, ****p < 0.0001 (ANOVA with Bonferroni
post hoc) compared to AMI untreated (scar, LVESV, LVEDV) or between apoCDC and CDC where indicated.
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studies have shown that individual APOSEC components or para-
crine factors derived from distinct PBMC subsets fail to fully replicate
functional APOSEC effects. In addition to the use as an active phar-
maceutical ingredient (API), our data show that APOSEC may hold
promise for enhancing properties or cardiac progenitor cells.
1 month after cell treatment, the differences in expression of the
investigated genes and miRNAs were small, and no distinct effects
of the treatment were identified. Of the investigated molecular
markers, the tissue expression of CXCL12 was increased significantly
in all groups compared to sham-operated animals, indicating a prom-
inent role of CXCL12 after infarct. CX43 expression was reduced in
infarcted areas but not the border or remote zones. We found a strong
inverse correlation between miR-1 and Cx43 expressions, confirming
the effect of miR-1 on its gene target CX43.
Limitations
This preclinical study was performed in healthy young animals, which
lack comorbidities frequently observed in human patients, such as hy-
pertension, atherosclerosis, diabetes, etc. Influences of these on the
scar size and LV dilation and remodeling are therefore disregarded
in this study.
A 1-month follow-up period (FUP) shows the scar size developed af-
ter ischemic injury. For development of chronic ischemic heart failure
and more detailed investigation of functional consequences of the
stem-cell therapy, a longer FUP of at least 2 or 3 months would be
required. We were thus unable to detect possible longer-term func-
tional improvements by either CDCs or apoCDCs in this study.
The animals did not receive standard medical treatment to prevent
LV dilation and remodeling (e.g., angiotensin-converting enzyme
[ACE] inhibitors, angiotensin receptor blockers [ARBs], or beta-
blockers). However, they were treated with the dual antiplatelet ther-
apies. The general health status of the animals was monitored on a
daily basis, but blood pressure, heart rate, electrocardiogram (ECG),
and laboratory values for a medical therapy guide were checked at
the final follow-up examination only. Any of the above-mentioned in-
formation would have required anesthesia, with the risk of anesthetic
complication of the animals with AMI.
Conclusion
We have identified protecting and beneficial effects of APOSEC on
CDCs in in vitro cell culture. Intracoronary infusion of apoCDCs in
the reperfusion phase of AMI led to significantly better myocardial
viability and lower transmurality in the infarcted area, demonstrated
by PET-MRI imaging.
Translational Outlook
Although cell preconditioning with APOSEC failed to translate into
robust enhancement of cardiac functional outcomes in a large-animal
AMI model, our data demonstrate an essential influence of cell-cul-
ture conditions on the paracrine signature of stem cells, and further
optimization is a viable strategy for rational improvement of stem
cells in cardiac applications. Hybrid PET-MRI imaging appears to
be more sensitive to assess cardiac repair therapy effects. Together
with reduced infarct scar sizes by CDCs and apoCDCs, these data




Porcine allogeneic CDCs were isolated as described.8 CDCs were re-
suspended (1.25 106/mL for a total dose of 12.5 106) in CryoStor
CS10 (BioLife Solutions) in Cryobags (PL07 PermaLife Bags; OriGen
Biomedical), placed directly in a CryoMed controlled-rate freezer and
then transferred to liquid nitrogen. Cells were prepared at the Smidt
Heart Institute, shipped to the Medical University of Vienna, and
thawed on site for in vitro preconditioning and in vivo experiments.
APOSEC Preparation
Porcine APOSEC was obtained as described.27 The obtained solution
was sterile filtered, frozen, and lyophilized overnight. Lyophilized
APOSEC aliquots were stored at 80C.
Figure 5. Number of Heart Segments in Different Groups with Reduced
(50%–75%) or Lack of Viability (<50%) Assessed by [18F]FDG-PET-MRI and
Number of Segments with Transmurality >50% and Nontransmural Scar
between 25% and 50% Assessed by Cardiac MRI
The number of transmural and nontransmural segments was lower after apoCDC
treatment, with fewer transmural segments after CDC treatment compared to
controls. Data are mean ± SEM. *p < 0.05 (ANOVA with Bonferroni post hoc)
compared to AMI untreated.
Figure 4. Segmental Analysis of Transmurality and [18F]FDG Uptake of Infarcted Porcine Hearts, 1 Month after Treatment with apoCDCs, CDCs, or Saline
Control
(A) Significantly lower transmurality was detected in mid-anteroseptal, inferoseptal, and apical segments in both CDC and apoCDC groups than in the untreated control
animals. (B) Significantly higher FDG uptake was found in apical-anterior, apical-septal, and apex regions in apoCDC-treated animals and in the apical-anterior segment in
CDC-treated animals compared to untreated controls. Data are mean ± SEM. *p < 0.05 (ANOVA with Bonferroni post hoc) compared to AMI untreated.
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In Vitro Effect of APOSEC on CDCs—Proteomics
Porcine CDCs were cultured in growth medium (Iscove’s modified
Dulbecco’s medium [IMDM], supplemented with 10% fetal calf
serum [FCS] and penicillin/streptomycin) in 5% CO2 at 37
C. Cells
were incubated with serum-free medium (4 mL), with or without
APOSEC, as detailed in the Supplemental Information. For proteo-
mic analysis, the proteins of the supernatant were subjected to la-
bel-free shotgun proteomics on a liquid chromatography (LC)/MS
system. Quantitative data were assessed by MACSQuant and pro-
cessed in R,28 with the limma package29 and clusterProfiler.30 Gene
expression was analyzed by qRT-PCR, and cytokine concentrations
were analyzed using commercial ELISA kits (porcine VEGF and
CXCL12/SDF-1; Sigma-Aldrich), as detailed in the Supplemental
Information.
APOSEC Pretreatment of CDCs for In Vivo Application
For APOSEC conditioning, CDCs were thawed, seeded in 300 cm2
flasks (1.6  107 cells per flask), and cultured in growth medium
(IMDM, 20% FBS, supplemented with gentamicin and b-mercap-
toethanol) for 24 h. The next day, growth medium was replaced
with fresh medium containing APOSEC (in a final concentration
of APOSEC derived from 10.0  106 cells/mL), and cells were
incubated for further 48 h. The supernatant was removed, and cells
were washed with PBS, trypsinized, and resuspended in CryoStor
CS10 and passed repeatedly through a gauge. Cell numbers were
counted, and the cell suspension was diluted to 1.7  106 cells/
mL (7 mL for one dose). Upon thawing, 1 mL 100 IU/mL heparin
and 0.1 mL nitroglycerin (50 mg/mL) were added to the cell
suspensions.
Animal Experiments
All applicable international, national, and/or institutional guidelines
for the care and use of animals were followed. All procedures were
performed with the approval of the local Ethical Committee of the
Experimental Animal Care Committee of the University of Kaposvár,
Hungary (approval reference: SOI/31/1220-6/2015 (KA-1777)), con-
forming to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health. The animals
were randomly assigned to groups AMI (n = 22) or control (n = 5)
(Figure 1). The pigs in AMI groups underwent a reperfused AMI pro-
tocol, whereas the control animals received only the catheterization.
One pig died during the AMI protocol. All other animals completed
the study period and were included in the analyses. Investigators were
blinded for PET/MRI imaging and downstream analyses.
Domestic pigs (female, 15 kg, n = 26) were fasted overnight and were
sedated with 12 mg/kg ketamine hydrochloride, 0.04 mg/kg atropine,
and 1.0 mg/kg xylazine, followed by intratracheal intubation. The
anesthesia was then continued with 1.5–2.5 vol% isoflurane, 1.6–1.8
vol% O2, and 0.5 vol% N2O. During anesthesia, continuous moni-
toring of the O2 saturation and ECG were performed. After surgical
preparation of the right arteria femoralis, a 6F introducer (Medtronic,
Minneapolis, MN, USA) was placed. After administration of 200 IU/
kg unfractionated heparin intra-arterially, 6F right coronary guiding
Figure 6. Analysis of Gene and miRNA Expression in Ischemic (AMI), Border, and Remote LV of Treated Pigs 1 Month after AMI and Receiving Stem Cell
Treatment
Control represents healthy (non-AMI) heart tissue. *p < 0.05 (ANOVA with Bonferroni post hoc) compared to healthy animals; compared to untreated where indicated.
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catheters were introduced into the left and right coronary ostium to
perform selective angiography of the left and right coronary arteries.
In the AMI pigs, the mid-left anterior descending artery (LAD) was
occluded by inflating a balloon (2.75 mm in diameter, 9–12 mm
long) at 5 atm for 90 min, followed by reperfusion via balloon defla-
tion. Immediately after induction of reperfusion, an additional dose of
2,000 IU heparin was administered in order to decrease microvascular
obstruction. 15 min after a control angiography (to prove the patency
of the infarct-related artery), an over-the-wire balloon was inserted
distal to the previously occluded site, and the CDCs (107 cells, sus-
pended in 20 mL saline with 2,000 IU heparin and 0.1 mL nitroglyc-
erin), with (group apoCDC, n = 8) or without APOSEC precondition-
ing (group CDC, n = 6) or saline solution (group AMI-untreated, n =
7), were infused (1 mL/min) into the LAD by selective intracoronary
infusion. After hemodynamic stabilization, the pigs were allowed to
recover.
All pigs received a standard loading dose of clopidogrel (300 mg)
and aspirin (250 mg), 1 day prior to the procedure, and the standard
postinfarction daily medical treatment of 100 mg aspirin and 75 mg
clopidogrel. Routine blood parameters (electrolyte, blood sugar, he-
matologic parameter, kidney, liver function) were monitored before
AMI, after reperfusion, and after the respective treatment, further-
more at 3 days and 30 days post-AMI. At the 3-day FUP, cardiac
[18F]FDG-PET-MRI with LE was performed to measure LV perfor-
mance and to identify the area at risk. This was repeated at the 30-
day FUP, accompanied by control invasive hemodynamic
assessments.
Follow-Up Investigations
After overnight fasting, all pigs in AMI groups underwent hybrid
[18F]FDG-PET-MRI with LE, whereas control animals received
MRI + LE without PET, 3 and 30 days after the sham procedure,
respectively. At the final 30 days follow-up, left-heart catheterization
was performed under general anesthesia to ensure the patency of the
infarct-related artery, followed by humane euthanasia by intravenous
application of 10 mL saturated potassium chloride. The hearts were
explanted, and myocardial samples from the infarcted border zone
of AMI and remote posterior-wall myocardial areas were immediately
cut and stored in RNAlater (QIAGEN, Germany). Myocardial sam-
ples from the mid-anterior region of the control animals were also
stored.
PET-MRI Imaging Acquisition
[18F]FDG-PET-MRI imaging was performed by using a hybrid PET/
MRI system (Biograph mMR; Siemens Medical Solutions, Erlangen,
Germany), allowing the simultaneous acquisition and analysis of
PET and MRI data in a one-step mode. The cardiac MRI part of
the acquisition has been performed by using a 3T MRI, whereas the
PET scanner is built of lutetium oxyorthosilicate (LSO) crystals
equipped with avalanche photodiodes.31
For the assessment of the cardiac function and the visualization of
possible wall-motion abnormalities, multislice-multiphase cine imag-
ing was performed in the long horizontal axis, as well as in the short
axis view through the entire heart.
Myocardial function and scar size were assessed by MRI after an
intravenous bolus of a contrast agent (0.05 mmol/kg gadobenate di-
meglumine [MultiHance, Bracco Imaging, Italy], 4 mL/s), with an
automatic injector (Medrad Spectris, USA). During administration
of the contrast agent with a power injector, time-resolved imaging
of three slices in the short axis and one slice in the horizontal long
axis was acquired to detect perfusion deficits. After a delay time of
at least 10 min after contrast agent injection, LE imaging (late gado-
linium enhancement [LGE]) was performed to assess myocardial scar
size. Prior to the acquisition of the LE sequence, a scout for the assess-
ment of the optimal inversion time (T1) was done. The LE imaging
was performed in the short axis and the 4- and 3-chamber views.
For PET imaging, a list-mode ECG-gated PET scan in 3D mode was
initiated 1 h after intravenous injection of 300 MBq [18F]FDG in
fasted animals, according to an established protocol.24 Blood sugar,
electrolyte, and kidney function were assessed prior to imaging acqui-
sition. Emission data correction was done for dead time, randoms,
scatter, and attenuation. A 3D attenuation-weighted ordered-subsets
expectation maximization (AW-OSEM 3D)-iterative reconstruction
algorithm with Gaussian smoothing at 4 mm full width at half
maximum and a matrix size of 344 344 were used for image recon-
struction. ECG-triggered long-axis (two- and four-chamber views)
and short-axis images were acquired during breath hold.
Table 2. Short Comparison of Imaging Techniques for Assessment of Myocardial Infarction
[18F]FDG-Positron Emission Tomography (PET) Magnetic Resonance Imaging (MRI)
Advantages high sensitivity, high accuracy for viability detection high spatial resolution, high accuracy for scar detection
Disadvantages exposure to ionizing radiation, lower spatial resolution lower specificity of LGE
Provided information in
heart imaging
myocardial viability, enhanced glucose uptake in inflammatory
cardiac diseases enhanced glucose uptake in hibernating
myocardium
myocardial function parameter: systolic and also diastolic,
infarct size, myocardial edema, area at risk
Limitations
interference of inflammation, cost, availability restricted to
specialized centers
interference by medical devices and metal implants
LGE, late gadolinium enhancement.
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Comparative Semiquantitative Analysis of Myocardial Viability
and Quantitative Assessment of LV Function by Hybrid PET-MRI
Imaging
TheEFs of both the LVandRV, aswell as further functional parameters,
includingESV,EDV, and stroke volume (SV),were calculated in a semi-
automatic fashion based on the short-axis views and were related to the
actual body weight (LV EDV index [EDVi], ESV index [ESVi], and SV
index [SVi]). The infarcted myocardial mass was determined based on
the LE MR images, and infarct size was calculated relative to the LV
mass and expressed as percentageof the entire LV.The infarct-sizemea-
surement was based on a semi-automatic approach, with the hyperin-
tense areas on MR images assessed 10 min after gadolinium contrast
agent administration. Infarct sizes were determined using the
MEAN+2SDmethod,whereMEANrefers to themean intensity values
of a remote (i.e., unaffected) myocardial segment, whereas the scar is
defined as image pixels with higher intensity values than the sum of
the mean plus two standard deviations of the unaffected myocardium.
Volumetric MRI analysis and infarct-size measurements were per-
formed using the freely available software Segment (Medviso AB,
Lund, Sweden).32 For semiquantitative assessment of infarct transmur-
ality, the LGE images were divided into 17 segments, according to the
American Heart Association (AHA) recommendation of 17-segment
analysis. Reference “no scar” zero point and 100% as transmural area
of the highest intensity in the LGE areas of the remote posterior and
infarcted areas were chosen, respectively, and the transmurality of
other segments was related to these values. Transmural, reduced trans-
murality, and no transmurality of the segments were defined as >75%,
25%–75%, and <25%, respectively, of intensity.
Quantitative segmental analysis of the attenuation-corrected PET im-
ages were performed by using the acquisition 60 min after [18F]FDG
tracer injection. In order to enable direct segmental comparison of
PET and MRI images, an in-house software was developed, and we
divided the myocardium to 17 segments. Segmental analysis was per-
formed by overlaying the linear borders of a 17-segment LV model
on the PET image.We visually controlled the location of themodel out-
lines on the PET-visible LV and RV borders on all slices that comprised
the heart volume from the apex to the level of the great vessels. Analysis
was consistently restricted to slices between the apex and the basis on
which the LV myocardium is seen in 360. The optimal rotation of
the 17-segment model around the apex-basis axis was determined by
matching the mid-septal points in the image and the model. The
endo- and epicardial borders were segmented based on the visual fea-
tures of the PET image. Tracer uptakewas calculated using a semiquan-
titative method. First, we calculated the average image intensity of a
given LV segment in the bulls-eye plot tool of Segment. The standard-
ized uptake value (%) of the tracer for each segment was calculated by
normalizing their values to the “hottest” LV segment. Nonviable seg-
ments were defined as <50% segmental tracer uptake.24 For a more
refined assessment, we additionally defined segments with 50%–75%
[18F]FDG uptake as having reduced viability.33
For quality control, we have performed quality check and reproduc-
ibility measurements by analyzing selected 1-month follow-up [18F]
FDG-PET-MRI images of ten randomly chosen animals, twice by
the same observer (intraobserver) and by two independent observers
(interobserver). Repeat measurements of the normalized FDG uptake
of the 17 segments of the ten images resulted in a regression coeffi-
cient of variation of the repeated analyses between 0.87 and 0.92
(p < 0.001) (intraobserver variability) and 0.81 and 0.89 (p < 0.001)
(interobserver variability).
Statistical Analyses
Statistical significance was calculated by comparing the groups using
ANOVA with Bonferroni post hoc analyses in SPSS statistics, version
21.0. Bivariate correlations were calculated using Pearson coefficient.
Statistical significance of proteomics data was calculated using
limma with voom transformation.29 PET-MRI and gene-expression
analyses were performed by blinded observers.
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